namilumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
namilumab

GtoPdb Ligand ID: 10370

Synonyms: AMG203 [5] | MT203

Compound class: Antibody

Comment: Namilumab (AMG203, MT203) is an IgG1κ anti-macrophage colony-stimulating factor (GM-CSF; CSF2) monoclonal antibody [2]. It is being developed by Micromet and Nycomed for the treatment of autoimmune and chronic inflammatory diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB entry.

No information available.

No information available.

Summary of Clinical Use
Phase 2 evaluation in a 12 week study has demonstrated the clinical efficacy effected by inhibiting macrophage activity via targeting of GM-CSF in patients with rheumatoid arthritis [5].

Summary of Clinical Use

Phase 2 evaluation in a 12 week study has demonstrated the clinical efficacy effected by inhibiting macrophage activity via targeting of GM-CSF in patients with rheumatoid arthritis [5].

Mechanism Of Action and Pharmacodynamic Effects
GM-CSF (CSF2) is a pro-inflammatory cytokine that is over-produced in many autoimmune and chronic inflammatory human diseases. Namilumab binds to this cytokine, neutralises its activity and mediates a reduction in inflammation in vitro and in preclinical in vivo models [2].

Mechanism Of Action and Pharmacodynamic Effects

GM-CSF (CSF2) is a pro-inflammatory cytokine that is over-produced in many autoimmune and chronic inflammatory human diseases. Namilumab binds to this cytokine, neutralises its activity and mediates a reduction in inflammation in vitro and in preclinical in vivo models [2].